Understanding blood biomarkers for Alzheimer's disease
Blood Amyloid, Tau, and Neurodegeneration Biomarkers and Prediction of Clinical Onset, Cognitive Decline, and Dementia Diagnosis
This study is testing if certain blood markers can help identify and predict Alzheimer's disease in people aged 60 and older.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1800 (estimated) |
| Ages | 60 Years and up |
| Sex | All |
| Sponsor | Washington University School of Medicine Academic / other |
| Locations | 1 site (St Louis, Missouri) |
| Trial ID | NCT06547099 on ClinicalTrials.gov |
What this trial studies
This study aims to explore the relationships between blood-based biomarkers, specifically amyloid, tau, and neurodegeneration, and their association with Alzheimer's disease pathology and cognitive decline. Eligible participants aged 60 and older will undergo initial cognitive assessments and blood collection, with follow-up visits for additional testing based on their cognitive status. The goal is to validate blood tests that could aid in the diagnosis and prediction of Alzheimer's disease.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 60 and older who exhibit symptoms of forgetfulness, mild cognitive impairment, mild dementia, or have a diagnosis of Alzheimer's disease.
Not a fit: Patients who are unable to perform basic daily activities due to cognitive impairment or those currently taking disease-modifying drugs for Alzheimer's may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the development of reliable blood tests for diagnosing Alzheimer's disease, improving early detection and management.
How similar studies have performed: Other studies have shown promise in using blood biomarkers for Alzheimer's diagnosis, indicating that this approach is gaining traction in the field.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * At least 60 years of age * 80% of the newly enrolled clinic-based cohort will have symptoms of forgetfulness, mild cognitive impairment, mild dementia, or Alzheimer's disease as determined by their medical chart and/or provider * All SEABIRD participants will be invited to participate regardless of their cognitive status Exclusion Criteria: * Unable to perform one or more basic activities of daily living (eating, bathing, dressing, ambulating, toileting) due to cognitive impairment * Uncontrolled hepatitis B, hepatitis C, or HIV at time of blood collection * Taking a disease-modifying drug for AD at time of enrollment * Blood transfusion in the last three months * Unwilling or unable to participate in all study activities
Where this trial is running
St Louis, Missouri
- Washington University School of Medicine — St Louis, Missouri, United States (Recruiting)
Study contacts
- Principal investigator: Randall Bateman, MD — Washington University School of Medicine
- Study coordinator: Lisa Soke
- Email: sunbirdstudy@wustl.edu
- Phone: 314-747-4857
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.